source
- Medicare’s new RAPID coverage pathway speeds adult device access, but pediatric devices still lagThe Centers for Medicare and Medicaid Services and the FDA introduced the Regulatory Alignment for Predictable and Immediate Device (RAPID) coverage pathway. The new process promises Medicare natio…
- Pimicotinib shows 76% response rate and functional benefits in TGCT phase 3 trialDr. Randall discussed results from the phase 3 MANEUVER trial of the CSF-1 receptor inhibitor pimicotinib in patients with tenosynovial giant cell tumor (TGCT). The data were presented at the 2025…